Related Experiment Video
Updated: Jun 29, 2025

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging
Published on: April 28, 2021
Loss of the DNA Repair Gene RNase H2 Identifies a Unique Subset of DDR-Deficient Leiomyosarcomas
Michael S Nakazawa1, Ian M Silverman2, Victoria Rimkunas2
1Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract:
Targeting the DNA damage response (DDR) pathway is an emerging therapeutic approach for leiomyosarcoma (LMS), and loss of RNase H2, a DDR pathway member, is a potentially actionable alteration for DDR-targeted treatments. Therefore, we designed a protein- and genomic-based RNase H2 screening assay to determine its prevalence and prognostic significance. Using a selective RNase H2 antibody on a pan-tumor microarray (TMA), RNase H2 loss was more common in LMS (11.5%, 9/78) than across all tumors (3.8%, 32/843). In a separate LMS cohort, RNase H2 deficiency was confirmed in uterine LMS (U-LMS, 21%, 23/108) and soft-tissue LMS (ST-LMS; 30%, 39/102). In the TCGA database, RNASEH2B homozygous deletions (HomDels) were found in 6% (5/80) of LMS cases, with a higher proportion in U-LMS (15%; 4/27) compared with ST-LMS (2%; 1/53). Using the SNiPDx targeted-NGS sequencing assay to detect biallelic loss of function in select DDR-related genes, we found RNASEH2B HomDels in 54% (19/35) of U-LMS cases with RNase H2 loss by IHC, and 7% (3/43) HomDels in RNase H2 intact cases. No RNASEH2B HomDels were detected in ST-LMS. In U-LMS patient cohort (n = 109), no significant overall survival difference was seen in patients with RNase H2 loss versus intact, or RNASEH2B HomDel (n = 12) versus Non-HomDel (n = 37). The overall diagnostic accuracy, sensitivity, and specificity of RNase H2 IHC for detecting RNA-SEH2B HomDels in U-LMS was 76%, 93%, and 71%, respectively, and it is being developed for future predictive biomarker driven clinical trials targeting DDR in U-LMS.
Insights
Loss of RNase H2 is common in uterine leiomyosarcoma (U-LMS) and may indicate actionable alterations for DNA damage response (DDR) targeted therapies. RNase H2 immunohistochemistry (IHC) shows promise as a predictive biomarker for U-LMS clinical trials.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Targeting the DNA damage response (DDR) pathway is a promising therapeutic strategy for leiomyosarcoma (LMS).
- RNase H2, a key member of the DDR pathway, represents a potential therapeutic target in LMS.
- Loss of RNase H2 function is an actionable alteration for DDR-targeted treatments.
Purpose of the Study:
- To develop and validate protein- and genomic-based assays to screen for RNase H2 loss in LMS.
- To determine the prevalence and prognostic significance of RNase H2 deficiency in different subtypes of LMS.
- To evaluate RNase H2 immunohistochemistry (IHC) as a predictive biomarker for DDR-targeted therapies in U-LMS.
Main Methods:
- Utilized RNase H2-specific antibody on a pan-tumor tissue microarray (TMA) to assess protein expression across various tumor types, including LMS.
- Analyzed RNase H2 deficiency in uterine LMS (U-LMS) and soft-tissue LMS (ST-LMS) cohorts.
- Employed targeted next-generation sequencing (NGS) assay (SNiPDx) to detect biallelic loss of function (HomDels) in RNASEH2B.
- Correlated RNase H2 protein levels with genomic alterations and clinical outcomes in U-LMS patients.
Main Results:
- RNase H2 loss was significantly more frequent in LMS (11.5%) compared to other tumors (3.8%).
- RNase H2 deficiency was confirmed in 21% of U-LMS and 30% of ST-LMS cases.
- RNASEH2B homozygous deletions (HomDels) were identified in 6% of LMS cases in the TCGA database, with a higher prevalence in U-LMS (15%).
- Targeted NGS detected RNASEH2B HomDels in 54% of U-LMS cases with RNase H2 loss by IHC.
- RNase H2 loss or RNASEH2B HomDel status did not significantly impact overall survival in U-LMS patients.
- RNase H2 IHC demonstrated 76% diagnostic accuracy, 93% sensitivity, and 71% specificity for detecting RNASEH2B HomDels in U-LMS.
Conclusions:
- RNase H2 deficiency is a prevalent alteration in LMS, particularly in U-LMS.
- RNase H2 IHC is a sensitive and specific method for detecting RNASEH2B HomDels in U-LMS.
- RNase H2 IHC shows potential as a predictive biomarker for DDR-targeted clinical trials in U-LMS.
- Further development of RNase H2 IHC is warranted for biomarker-driven clinical trials in U-LMS.
Related Concept Videos
DNA Damage can Stall the Cell Cycle
Base Excision Repair
The first step of...
Nucleotide Excision Repair
Abnormal Proliferation
DNA Damage Can Stall the Cell Cycle
Overview of DNA Repair
Chemically...

